Latest Headlines

Latest Headlines

AstraZeneca, Astellas among Optimer bidders, Bloomberg sources say

Who wants Optimer Pharmaceuticals and its high-powered antibiotics? A handful of drugmakers, apparently.

Astellas chops OSI, Perseid ops in global R&D restructuring

Tokyo-based Astellas Pharma is rolling out a major R&D restructuring effort, shuttering facilities at its OSI Pharmaceuticals and Perseid Therapeutics subsidiaries and cutting back its work at the Astellas Research Institute of America to focus solely on CNS diseases.

Pharma giants' oral EPO alternatives could cater to dopers

GlaxoSmithKline CEO Andrew Witty has high hopes for an experimental pill his company is developing for anemia, as the drug could offer an oral alternative to injected EPO therapies.

GSK, Astra among shoppers for $1B Optimer deal: Bloomberg

Drugmakers are circling Optimer Pharmaceuticals, the antibiotics maker that says it's considering a sale. And that includes GlaxoSmithKline, Astellas Pharma, AstraZeneca and Cubist Pharmaceuticals, Bloomberg sources say, for a deal worth as much as $1 billion.

Cubist Pharma buys out antibiotic partner Astellas for $25M-plus

Lexington, MA-based Cubist Pharmaceuticals has bought out Astellas' rights to ceftolozane, putting up $25 million in cash for an antibiotic that has demonstrated some promising outcomes in clinical studies.

Zytiga, Xtandi will help pump prostate cancer market to $9.1B

The market for prostate cancer drugs is expected to double by 2021 to $9.1 billion, thanks in part to the debut of new, more expensive drugs. According to Decision Resources, Johnson & Johnson's ($JNJ) Zytiga, along with Medivation ($MDVN) and Astellas Pharma's new Xtandi, will help drive sales growth in 7 major drug markets.

Ironwood wins first big approval on blockbuster hopeful linaclotide

Cambridge, MA-based Ironwood cleared a major milestone in its development this morning, winning an FDA approval for linaclotide and paving the way for its big leap into commercialization.

Upbeat PhIII results bolster Medivation's big plans for prostate cancer

Medivation has added another set of stellar data on enzalutamide, its promising prostate cancer treatment now up for a priority review at the FDA. New late-stage results published in the New England Journal of Medicine indicate that advanced stage, therapy-resistant patients in the drug arm survived 5 months longer than the control group.

Astellas nabs critical FDA OK for new overactive bladder pill mirabegron

Back in April, several of the outside experts brought in for an FDA panel session fretted over Astellas's mirabegron, an experimental drug for overactive bladder. The staff review had already raised serious questions about increased heart rates, along with painful rashes and anemia. But Astellas won the vote 7-4. And now it has gone on to pick up the formal approval.

INC Research to close another facility, laying off around 30

INC is facing another facility closure. Its clinical study unit in Morgantown, WV will be shut down, according to a story by  The State Journal.